Fortis Healthcare Reports Q4 FY2024-25 Results: Revenue Increased by 12.4%, Net Profit Plummets by 7.4%
New Delhi: Corporate hospital chain Fortis Healthcare reported Q4 FY2024-25 results, showing a year-on-year (YoY) revenue increase of 12.4% to ₹2,007 crore. The net profit, however, fell by 7.4% to ₹188 crore, though the operating margin improved to 21.7%, reaching ₹435 crore.
In Q4, Fortis’ recently launched Manesar facility saw lower-than-average demand, with bed occupancy at 38% on 77 in-operation beds. The average revenue per occupied bed rose to ₹2.67 crore from the fiscal’s previous average of ₹2.51 crore.
International patients’ revenue contributed 8.1% to overall business revenue, marking a marginal uptick from the preceding fiscal’s 7.9% growth. The company’s net debt increased to ₹1,694 crore, with a net debt-to-EBITDA ratio and net debt-to-equity both surpassing prior levels.
In Q4, the hospital’s majority revenue growth was attributed to an 84% share of the consolidated revenue and a 16% YoY increase in oncology, neurosciences, cardio sciences, gastroenterology, orthopedics, and renal science revenue.
COVID-19 diagnostics revenues surged by 40% YoY. Additionally, Dr. Ashutosh Raghuvanshi, MD and CEO of Fortis Healthcare, underscored steady improvements in diagnostic business EBITDA margins and the brand’s growing prominence. The company will recommend a ₹1 per share dividend.
Updated: May 21, 2025, at 5:41 PM IST
For more updates, subscribe to ETHealthworld’s newsletter: [Link to Newsletter]
